BMAC treatment may be considered for selected joint, tendon, ligament, orthopedic, hypermobility, or joint instability pain patterns.
Bone Marrow Aspirate Concentrate (BMAC) is a regenerative medicine treatment that uses concentrated cells from your own bone marrow to support healing in injured joints, tendons, ligaments, and other musculoskeletal tissues. Dr. Siefferman explains how BMAC works, who may benefit from it, and when it may be considered as an alternative to surgery or other treatments.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Jason Siefferman, medical director at Manhattan Pain Medicine. When we’re looking at a painful structure where there has been some injury, we question how can we best heal the structure. Will it heal on its own? Has it failed to heal on its own? Will physical therapy be adequate? Or do we need to do something to bolster that healing process?
Regenerative medicine is a category of injections where we actually stimulate a healing response through the body’s natural inflammatory cascade. And we generally have two or three main modalities that we use for this.
First, prolotherapy. Prolotherapy stands for proliferation therapy. We do this with dextrose, which is sugar. What the sugar does is it chemically irritates the tissues and stimulates a healing response directly. What’s nice about prolotherapy is that we can include local anesthetic with it. So, we also achieve a diagnostic block, which means we can confirm if that structure is indeed causing the pain we think it is. Any pain coming from that structure will be gone because it’s numb. If patients respond to prolotherapy, fantastic. This is something we can do a series of and we should see sequential improvement with each injection.
PRP is a more robust option. This is where we draw the patient’s blood, spin it down, we get the platelets, then we inject those platelets directly into the injured structures. This cannot be combined with local anesthetic because it actually deactivates the platelets. It is much more uncomfortable. It’s also a little bit more expensive because there’s a process of drawing the blood and spinning it down.
The healing effect from PRP is generally more robust than prolotherapy. So if there’s a torn meniscus or a labrum, PRP is generally a better choice for these, meaning you can get a more durable healing response with fewer injections. After PRP, of course, there’s bone marrow aspirate concentrate. There are other more advanced regenerative techniques, but generally if the first two are used appropriately, we don’t need to escalate to the more extravagant or expensive. Although many people are interested in stem cells, they’re generally not necessary.
By understanding, reverse engineering the mechanical cascade of why the pain is generating, we can identify the structures that need to be treated, choose the best treatment for those structures, and then get the patient to a healed place. By reverse engineering the process, understanding the mechanics that are causing the ongoing injury or lack of healing and treating those directly, specifically with the best form of regenerative medicine, we can generally help the patient find healing.
Bone marrow aspirate concentrate, or BMAC, is an orthobiologic procedure that uses a patient’s own bone marrow aspirate, which is collected, processed, and concentrated before being injected into a selected musculoskeletal target when clinically appropriate. BMAC treatment may be considered for certain joint, tendon, ligament, orthopedic, hypermobility-related, or joint instability pain patterns.
At Manhattan Pain Medicine, BMAC treatment NYC care begins with diagnosis-first evaluation. The goal is to determine whether the pain source, tissue target, imaging, symptoms, and recovery plan support BMAC, rather than treating it as a cure-all or a guaranteed alternative to surgery.
MPM specialists evaluate whether BMAC may be appropriate by identifying the likely pain generator before recommending treatment. Joint pain, tendon pain, ligament pain, labral symptoms, meniscal symptoms, shoulder pain, hip pain, knee pain, TFCC injury, hypermobility-related pain, and joint instability can come from different structures and may require different treatment plans.
MPM reviews the diagnosis, exam findings, imaging, prior injections, physical therapy response, instability patterns, orthopedic history, inflammatory contributors, nerve symptoms, and functional goals. This helps determine whether BMAC, PRP, prolotherapy, rehabilitation, ultrasound-guided injections, surgery consultation, or another pathway is the better fit.
Many patients search for BMAC therapy in Manhattan after persistent orthopedic or musculoskeletal pain has not improved enough with physical therapy, medication, steroid injections, PRP, prolotherapy, bracing, or surgery consultation. Others are interested in BMAC because they have heard it described as a “stem cell” or regenerative option.
MPM approaches BMAC carefully and avoids overpromising. BMAC is not the same as commercial stem cell therapy, exosome therapy, amniotic products, cord blood products, Wharton’s jelly products, or other marketed regenerative treatments. Many of those products are not FDA-approved for orthopedic pain or chronic pain conditions. BMAC may be considered for selected musculoskeletal targets, but it is not appropriate for every patient or every diagnosis. Evidence varies by condition, and results are not guaranteed. MPM focuses on accurate diagnosis, careful target selection, imaging review, ultrasound guidance when appropriate, informed consent, and rehabilitation planning.
BMAC may fit within MPM’s Musculoskeletal issues and Hypermobility expertise when a specific joint, tendon, ligament, or orthopedic pain generator is identified. Patients with chronic joint pain, tendon injury, ligament injury, labral symptoms, meniscal symptoms, shoulder pain, hip pain, knee pain, TFCC injury, hypermobility, EDS-related pain, or joint instability often need a plan that accounts for biomechanics, tissue tolerance, strength, stability, and functional goals.
BMAC is not a cure for EDS, hypermobility, arthritis, joint instability, tendon injuries, ligament injuries, labral tears, meniscal tears, spine pain, or complex chronic pain. For selected patients, it may be one part of a broader plan that also includes bracing, rehabilitation, activity modification, PRP, prolotherapy, ultrasound-guided injections, medication management, or specialist coordination.
Before BMAC treatment, MPM reviews the diagnosis, target structure, expected goals, risks, alternatives, preparation instructions, and recovery plan. During the procedure, bone marrow aspirate is collected from the patient, often from a pelvic bone region, then processed to create bone marrow aspirate concentrate. The concentrate is then injected into the selected joint, tendon, ligament, or musculoskeletal target when clinically appropriate. Ultrasound guidance may be used to support more precise placement.
Patients may feel soreness at the collection site and injection site, along with temporary pain flare, bruising, or stiffness. Recovery varies depending on the area treated, diagnosis, and procedure plan. Some patients may need activity modification, bracing, or gradual rehabilitation. Relief, if it occurs, may be gradual and is not guaranteed.
These guys are the best. I've been going here for over 6 years and their familiarity with my Schwannomatosis (most ppl have never even heard of it - its rather rare) and their ability to diagnose my CRPS quickly and accurately and then treat it like I was merely getting a flu shot is just incredible...
Highly recommended for those who need Pain Management. Everyone at Manhattan Pain Medicine is extremely nice and helpful. I have had very good interactions with both Dr. Siefferman and Dr. Louis. All of the staff is very responsive. 5 stars.
The providers at Manhattan Pain Medicine are exceptional. I wish I had found them 30 years ago!
I genuinely can’t say enough good things about the team at Manhattan Pain Medicine. I have MCAS, EDS, and an inflammatory autoimmune disease, and I’ve basically been searching for answers since I was a kid. I had years of unexplained inflammation markers, chronic pain, and allergic reactions despite...
I have a complex medical history and have seen a lot of doctors over the years. Dr. Mikaberidze and Dr. Siefferman each took the time to really listen and understand everything I had been dealing with. I also appreciated how they work together and communicated about my care. I left with a plan that...
Sharing my gratitude for the pleasant experience last week during my visit, the medical team provided great care and also treated my session as a learning experience, I left my session with a wealth of knowledge. A big thank you to the kind, and professional staff who welcomed me to the office as a...
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
Dr Siefferman is the most thorough, patient doctor I have even been to. Currently I travel from miami to nyc to see him because his bed side manner and desire to help is incomparable.
ZocDoc
This practice is wonderful. I have been a patient of Dr. Siefferman’s since 2019 and he’s extremely helpful and kind. He has brought in a Rheumatologist who is also great. They handle very complex pain issues and always try to find new ways to help me.
Dr. Siefferman is an incredible doctor! He is extremely diligent and knowledgeable. It feels like you are his only patient. He invests a lot of time and effort into your injuries and concerns. I did not find these wonderful qualities with other pain specialists before, who were always rushed and som...
ZocDoc
Dr. Siefferman is a doctor who combines the old world bedside manner of doctors from my childhood (60 years ago) with a sta te of the art embrace of modern technology. It is always a pleasure to have an appointment with him...always has options and solutions to my medical issues. He is truly the doc...
ZocDoc
Dr. Siefferman is a genius. He is very informed and listens attentively.
ZocDoc
Dr. Siefferman and his entire team continue to be efficient, dedicated, and driven by precision and a genuine desire to give fantastic care. Will always recommend.
ZocDoc
Doctor Siefferman is fantastic. Have been seeing him for 5 years. Couldn’t recommend more.
ZocDoc
Dr. Siefferman is the ONLY doctor who has ever been able to diagnose my pain and treat it. He is hands down the best
ZocDoc
BMAC stands for bone marrow aspirate concentrate. It is an orthobiologic procedure that uses a patient’s own bone marrow aspirate, which is collected, processed, and concentrated before being injected into a selected musculoskeletal target. BMAC may be considered for certain joint, tendon, ligament, orthopedic, hypermobility-related, or joint instability pain patterns when clinically appropriate. It is not a cure-all and is not appropriate for every condition. MPM evaluates the diagnosis and target before considering BMAC treatment NYC care.
Bone marrow aspirate concentrate means that bone marrow fluid is collected from the patient and processed to concentrate selected components before being used in a targeted procedure. In musculoskeletal care, BMAC may be injected into selected joints, tendons, ligaments, or orthopedic targets when the diagnosis supports it. It should not be described as guaranteed tissue regeneration or as a universal stem cell cure. MPM explains the procedure, rationale, risks, and alternatives before treatment.
BMAC is often marketed as “stem cell therapy,” but that language can be misleading. BMAC contains a mixture of cells and signaling components from the patient’s own bone marrow, but it is not the same as commercial stem cell, exosome, amniotic, cord blood, Wharton’s jelly, or adipose-derived products. Many marketed regenerative products are not FDA-approved for orthopedic pain or chronic pain conditions. MPM uses careful, regulation-aware language and avoids unsupported regenerative claims.
BMAC is collected by aspirating bone marrow from the patient, commonly from a pelvic bone region. The aspirate is then processed to create a concentrated preparation. The concentrate may then be injected into a selected musculoskeletal target when clinically appropriate. The procedure may involve soreness at the collection site and the injection site. MPM reviews preparation, technique, risks, recovery expectations, and whether ultrasound guidance may be used before treatment.
BMAC and PRP are different orthobiologic treatments. PRP is made from the patient’s blood and processed to concentrate platelets. BMAC is made from the patient’s bone marrow aspirate and contains a different mixture of cells and signaling components. Both may be considered for selected musculoskeletal conditions, but they have different collection methods, preparation steps, risks, costs, evidence limits, and recovery considerations. MPM determines which option, if either, fits the diagnosis and tissue target.
BMAC and prolotherapy are different regenerative medicine approaches. BMAC uses concentrated bone marrow aspirate from the patient. Prolotherapy typically involves injecting a solution, often dextrose-based, into selected ligament, tendon, joint, or instability-related targets to stimulate a local tissue response. Each option has different procedural steps, clinical uses, evidence limits, recovery expectations, and costs. MPM evaluates the diagnosis, tissue target, instability pattern, and goals before recommending either approach.
BMAC may be considered for selected musculoskeletal conditions involving joint pain, tendon pain, ligament pain, orthopedic injury, knee pain, hip pain, shoulder pain, labral symptoms, meniscal symptoms, TFCC injury, or hypermobility-related joint instability. It is not appropriate for every condition and should not be used as a substitute for diagnosis, rehabilitation, surgery, rheumatology care, neurology care, or other specialist evaluation when those are needed. MPM determines candidacy based on the full clinical picture.
BMAC may be considered for selected joint pain patterns depending on the diagnosis, joint involved, tissue condition, severity, and treatment goals. Some patients ask about BMAC for knee pain, hip pain, shoulder pain, arthritis-related pain, or orthopedic symptoms. BMAC does not cure arthritis or guarantee cartilage regrowth. Joint pain may also come from ligament instability, tendon irritation, nerve pain, inflammatory disease, or referred spine pain. MPM evaluates the pain generator before recommending treatment.
BMAC may be considered for selected tendon or ligament pain patterns when the tissue target, diagnosis, and recovery plan support the procedure. Tendon or ligament pain may involve degeneration, strain, partial injury, instability, overuse, inflammation, or poor movement mechanics. BMAC is not appropriate for every injury. Some patients may need physical therapy, bracing, PRP, prolotherapy, diagnostic ultrasound, additional imaging, or surgical evaluation instead.
BMAC may be considered for selected patients with hypermobility or EDS-related pain when a specific joint, tendon, ligament, or instability-related target is identified. It does not cure EDS, hypermobility spectrum disorder, joint instability, or complex chronic pain. Patients with hypermobility often need coordinated care that may include stabilization, bracing, physical therapy, pacing, and evaluation for overlapping nerve or centralized pain. MPM evaluates candidacy carefully before recommending BMAC.
BMAC may be considered for selected arthritis-related pain patterns, but evidence varies and it should not be presented as a cure for arthritis or a way to reliably regrow cartilage. Arthritis pain can also overlap with ligament strain, tendon pain, inflammation, nerve irritation, joint instability, or altered mechanics. MPM evaluates the diagnosis, severity, imaging, prior treatments, and realistic treatment goals before considering BMAC for arthritis-related pain.
Regulatory status depends on the specific procedure, preparation, and use. BMAC is an autologous orthobiologic procedure, but BMAC treatment should not be described as FDA-approved stem cell therapy for arthritis, orthopedic pain, chronic pain, spine pain, or neurologic conditions. Many marketed regenerative products, including stem cell and exosome products, are not FDA-approved for orthopedic pain or chronic pain. MPM discusses regulatory considerations, evidence limits, risks, and alternatives before treatment.
Insurance coverage for BMAC varies and is often limited. Many plans may consider BMAC investigational or may not cover it for certain orthopedic or pain conditions. Coverage depends on the payer, diagnosis, policy, and procedure details. Patients should confirm benefits, authorization requirements, and out-of-pocket costs before treatment. MPM can help clarify the clinical rationale for BMAC, but insurance decisions depend on the insurer and specific policy.
Risks may include bone marrow harvest pain, post-procedure pain flare, soreness, bruising, bleeding, infection, allergic reaction, nerve irritation, vascular injury, temporary worsening, incomplete relief, and persistent symptoms despite treatment. Risk depends on the collection site, injection target, technique, medical history, and recovery plan. Urgent evaluation is needed for fever, spreading redness, severe swelling, new weakness, new numbness, loss of pulses, limb discoloration, bowel or bladder dysfunction, or rapidly worsening symptoms.
MPM considers the diagnosis, pain generator, tissue target, imaging, exam findings, prior treatments, medical history, medication use, activity goals, instability patterns, inflammatory disease, nerve involvement, and rehabilitation plan. BMAC may be considered when the target is clear and the expected benefits justify the risks, recovery, and cost. If another option is more appropriate, MPM may recommend PRP, prolotherapy, ultrasound-guided injections, physical therapy, bracing, medication management, or specialist evaluation.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
Bone marrow aspirate concentrate, or BMAC, is an orthobiologic treatment made from a patient’s own bone marrow aspirate. The bone marrow sample is collected, processed, and concentrated, then injected into a selected musculoskeletal target when clinically appropriate. BMAC treatment may be considered for certain joint, tendon, ligament, orthopedic, hypermobility-related, or joint instability pain patterns.
At Manhattan Pain Medicine (MPM), BMAC treatment NYC care begins with diagnosis-first evaluation. The goal is to determine whether the patient has a clear pain generator that may reasonably fit a BMAC approach. BMAC is not a cure-all, a guaranteed alternative to surgery, or a replacement for rehabilitation, medical management, or appropriate specialist care.
BMAC may be considered for selected patients with persistent joint pain, tendon pain, ligament injury, orthopedic pain, knee pain, hip pain, shoulder pain, labral symptoms, meniscal symptoms, TFCC injury, or instability-related symptoms. Patients may ask about BMAC after trying physical therapy, medications, steroid injections, PRP, prolotherapy, bracing, or surgery consultation.
The potential role of BMAC depends on the diagnosis. A patient with joint degeneration may need a different plan than a patient with tendon injury, ligament instability, labral symptoms, meniscal symptoms, nerve irritation, inflammatory disease, or referred spine pain. MPM evaluates the structure involved, symptom duration, imaging findings, prior treatments, activity goals, and recovery plan before recommending treatment.
BMAC is sometimes described as a stem cell treatment, but that language can create unrealistic expectations. BMAC contains a mixture of cells and biologic signaling components from the patient’s own bone marrow, but it should not be presented as guaranteed regeneration or FDA-approved stem cell therapy for orthopedic pain.
Patients should be cautious about broad claims involving stem cell, exosome, amniotic, cord blood, Wharton’s jelly, or adipose-derived products marketed for arthritis, orthopedic pain, chronic pain, back pain, hip pain, knee pain, shoulder pain, or neurologic conditions. Many of these products are not FDA-approved for those uses. MPM focuses on responsible orthobiologic care, informed consent, and realistic expectations.
BMAC, PRP, and prolotherapy are different procedures. PRP is made from the patient’s blood and processed to concentrate platelets. Prolotherapy usually involves an injected solution, often dextrose-based, directed at selected ligament, tendon, joint, or instability-related targets. BMAC is prepared from bone marrow aspirate and has different collection steps, risks, costs, and evidence considerations.
No single regenerative treatment is best for every patient. MPM determines whether BMAC, PRP, prolotherapy, ultrasound-guided injections, rehabilitation, bracing, medication management, or surgery consultation is most appropriate based on diagnosis and goals.
Patients with EDS, hypermobility spectrum disorder, or joint instability may ask whether BMAC can help. BMAC may be considered only when a specific joint, tendon, ligament, or instability-related target is identified. It does not cure EDS, hypermobility, joint instability, or complex chronic pain.
Hypermobility-related pain often requires stabilization, physical therapy, bracing, pacing, activity modification, and evaluation for overlapping nerve or centralized pain. BMAC may be one option for selected targets, but the broader care plan is essential.
BMAC evidence varies by condition, target, and patient factors. Some patients may experience pain or function improvement, while others may not respond. BMAC should not be described as guaranteed cartilage regrowth, ligament reconstruction, disc regeneration, nerve regeneration, or permanent repair.
After BMAC, patients may experience soreness at the bone marrow collection site, soreness at the injection site, bruising, stiffness, or a temporary pain flare. Recovery may require activity modification, bracing, gradual loading, and physical therapy depending on the target and diagnosis.
Risks may include bone marrow harvest pain, post-procedure pain flare, bruising, bleeding, infection, allergic reaction, nerve irritation, vascular injury, temporary worsening, incomplete relief, and persistent symptoms despite treatment.
Patients should seek urgent evaluation for fever, spreading redness, severe swelling, new weakness, new numbness, bowel or bladder dysfunction, saddle anesthesia, chest pain, shortness of breath, sudden severe headache, severe abdominal or pelvic pain, major trauma, suspected infection, loss of pulses, limb discoloration, or rapidly worsening symptoms.
For selected patients, BMAC may be one part of a musculoskeletal or hypermobility-aware pain care plan. MPM’s role is to determine whether the diagnosis, tissue target, safety profile, evidence, and recovery plan support treatment within a coordinated, medically responsible framework.
